Search
Displaying 401–410 of 726 for “retinal diseases”
-
Nanoscope Therapeutics Launches Phase 2b Clinical Trial for Optogenetic Therapy
Research NewsWhile the trial is for people with RP, the company hopes it will also benefit people with other retinal degenerative diseases
-
AGTC Continues to Report Encouraging Data from its Phase 1/2 XLRP Gene Therapy Clinical Trial
Research NewsThe company is planning the launch of a Phase 2/3 trial for its XLRP gene therapy
-
A Eureka Moment for Paul Yang Boosts Advancement of Vision-Saving RP Drug
Research NewsHis latest Foundation grant is helping move the drug toward a clinical trial
-
Erin’s Unwavering Determination, Then and Now
Beacon StoriesDiagnosed with retinitis pigmentosa at a very young age, growing up, Erin never let her progressive vision loss stop her from keeping up with her friends and siblings. Throughout the 1990s, Erin was featured in several Foundation Fighting Blindness campaigns to raise funds for retinal research. Today, 34-year-old Erin is resilient as ever, still hopeful research will one day find her a cure.
-
Biogen Entering into Licensing Agreement with Mass Eye and Ear to Develop PRPF31 Gene Therapy
Research NewsThe goal of the partnership is to advance a PRPF31 gene therapy into a clinical trial
-
VisionWalk Home Page
-
AGTC Announces Development of Stargardt Disease Gene Therapy
Research NewsDual-vector delivery system designed to deliver the large ABCA4 gene
-
First Patient Receives ProQR’s Emerging USH2A Therapy in Clinical Trial
Research NewsProQR, a developer of RNA therapies in the Netherlands, announced that the first clinical-trial participant has received its emerging treatment, which targets retinitis pigmentosa and Usher syndrome caused by mutations in exon 13 of the USH2A gene.
-
Clinical Trial Authorized in the U.S. for Emerging LCA 10 Therapy
Research NewsProQR, a biotechnology company in the Netherlands, has received authorization from the U.S. Food and Drug Administration to start a Phase I/II clinical trial for its therapy known as QR-110
-
First Patient Treated in XLRP Gene Therapy Clinical Trial
Research NewsThe Nightstar gene therapy involves injection of healthy copies of RPGR underneath the retina.
.jpg)
